NCT02230228View on ClinicalTrials.gov

Phase 1 Safety Study of ALK-001 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

February 28, 2015

Conditions
Stargardt DiseaseAge-related Macular DegenerationOther Retinal Dystrophies
Interventions
DRUG

ALK-001 (No generic name)

Daily, oral administration of ALK-001 capsules.

Sponsors
All Listed Sponsors
lead

Alkeus Pharmaceuticals, Inc.

INDUSTRY